Christine Funke, MD
Glaucoma Specialist · Phoenix, AZNPI 1063703734
Payments from drug & device makers
Across 679 payments — averaging $664.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$181K
- Alcon$91K
- Glaukos Corporation$86K
- AbbVie$37K
- Sight Sciences, Inc.$23K
- Ivantis, Inc$12K
- plus $22K from 24 others
What the payments were for
- Consulting fees$120,56947%
- Speaking & faculty fees$100,21439%
- Travel & lodging$15,3026%
- Food & beverage$19,0627%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 11 | $180,526 |
| Alcon | 190 | $90,743 |
| Glaukos Corporation | 140 | $85,653 |
| AbbVie(2 entities) | 102 | $37,152 |
| Sight Sciences, Inc. | 59 | $22,802 |
| Ivantis, Inc | 18 | $11,941 |
| Nova Eye, Inc. | 6 | $11,913 |
| NEW World Medical,inc. | 51 | $3,359 |
| Rxsight Inc | 3 | $2,539 |
| Apellis Pharmaceuticals, Inc. | 2 | $2,023 |
| Aerie Pharmaceuticals, Inc. | 40 | $847 |
| Bausch & Lomb Americas Inc. | 14 | $518 |
| Biotissue Holdings Inc. | 5 | $182 |
| Novartis | 13 | $175 |
| Carl Zeiss Meditec USA, Inc. | 1 | $95 |
| Regeneron Healthcare Solutions, Inc. | 2 | $62 |
| Amgen(2 entities) | 3 | $54 |
| Astellas Pharma US Inc | 2 | $44 |
| Dompe US, Inc. | 1 | $44 |
| Sun Pharmaceutical Industries Inc. | 2 | $43 |
| Kala Pharmaceuticals, Inc. | 2 | $39 |
| Ocular Therapeutix, Inc. | 2 | $33 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $32 |
| Mallinckrodt Hospital Products Inc. | 1 | $32 |
| Tarsus Pharmaceuticals, Inc. | 1 | $29 |
| Genentech USA, Inc. | 1 | $28 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $28 |
| Abbott | 1 | $24 |
| Rayner Intraocular Lenses Limited | 1 | $21 |
| Biogen | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$97,673
- Voyager DSLT$32,869
- DURYSTA$24,029
- Travoprost Intraocular Implant - iDose$23,153
- OMNI(R) SURGICAL SYSTEM (US)$21,828
- SION SURGICAL INSTRUMENT$15,031
- XEN GLAUCOMA TREATMENT SYSTEM$9,745
- Kahook Dual Blade$2,558
- Clearpath$2,558
- Ahmed Glaucoma Valve$2,558
- Streamline$2,558
- iDoseTR$2,545
- RXSIGHT CONTACT LENS$2,500
- RXSIGHT INJECTOR CARTRIDGE$2,500
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$2,500
- LIGHT ADJUSTABLE LENS (LAL)$2,500
- RXSIGHT INJECTOR HANDPIECE$2,500
- Via360$2,400
- Rocklatan$2,388
- Syfovre$1,993
How this compares
Too few glaucoma specialist providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 122 | $72,770 |
| RocklatanNetarsudil Mesylat/Latanoprost | 61 | $42,274 |
| RhopressaNetarsudil Mesylate | 57 | $36,823 |
| Prednisolone Acetate | 738 | $31,181 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 85 | $24,604 |
| CombiganBrimonidine Tartrate/Timolol | 65 | $21,931 |
| VyzultaLatanoprostene Bunod | 36 | $19,041 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 110 | $17,949 |
| Brimonidine Tartrate | 380 | $15,660 |
| Latanoprost | 871 | $11,611 |
| Travoprost | 51 | $9,189 |
| Alphagan PBrimonidine Tartrate | 20 | $8,866 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 417 | $7,953 |
| Timolol Maleate | 369 | $7,273 |
| Dorzolamide Hcl | 302 | $7,143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $37,152 | $103,567207 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $847 | $79,096118 claims |
| AlconSimbrinza | $90,743 | $24,60485 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $518 | $19,04136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Phoenix
- Max KimPhoenix$486K
- Neil AtodariaPhoenix$97K
- Tara GolischPhoenix$3K
- Howard BerlinPhoenix$937
- Andrew RabinowitzPhoenix$396
- John LewisMesa$61K
- Robert SpurnyMesa$5K
- David KayMesa$4K
- Trenton BowenGilbert$4K
- Michael CampionScottsdale$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.